These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 33184050)

  • 1. Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial.
    Schuhmacher J; Heidu S; Balchen T; Richardson JR; Schmeltz C; Sonne J; Schweiker J; Rammensee HG; Thor Straten P; Røder MA; Brasso K; Gouttefangeas C
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33184050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
    Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer.
    Kouiavskaia DV; Berard CA; Datena E; Hussain A; Dawson N; Klyushnenkova EN; Alexander RB
    J Immunother; 2009; 32(6):655-66. PubMed ID: 19483644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
    Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
    Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First in man study: Bcl-Xl_42-CAF
    Mørk SK; Kongsted P; Westergaard MCW; Albieri B; Granhøj JS; Donia M; Martinenaite E; Holmström MO; Madsen K; Kverneland AH; Kjeldsen JW; Holmstroem RB; Lorentzen CL; Nørgaard N; Andreasen LV; Wood GK; Christensen D; Klausen MS; Hadrup SR; Thor Straten P; Andersen MH; Svane IM
    Front Immunol; 2023; 14():1122977. PubMed ID: 36999039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1/2a study to test the safety and immunogenicity of a p16(INK4a) peptide vaccine in patients with advanced human papillomavirus-associated cancers.
    Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Kloor M; Prigge ES; Sauer M; Al-Batran SE; Kaufmann AM; Schneider A; Jäger E; von Knebel Doeberitz M
    Cancer; 2016 May; 122(9):1425-33. PubMed ID: 26949913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UV1: long-term follow-up of three phase I clinical trials.
    Ellingsen EB; Aamdal E; Guren T; Lilleby W; Brunsvig PF; Mangsbo SM; Aamdal S; Hovig E; Mensali N; Gaudernack G; Inderberg EM
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35613827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
    Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer.
    Abdul Sater H; Marté JL; Donahue RN; Walter-Rodriguez B; Heery CR; Steinberg SM; Cordes LM; Chun G; Karzai F; Bilusic M; Harmon SA; Turkbey IB; Choyke PL; Schlom J; Dahut WL; Madan RA; Pinto PA; Gulley JL
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32269146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
    J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival.
    Thomas-Kaskel AK; Zeiser R; Jochim R; Robbel C; Schultze-Seemann W; Waller CF; Veelken H
    Int J Cancer; 2006 Nov; 119(10):2428-34. PubMed ID: 16977630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
    Zelba H; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Seibold M; Harter J; Latzer P; Hadaschik D; Battke F; Golf A; Rettig MB; Biskup S
    Front Immunol; 2023; 14():1271449. PubMed ID: 37920460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial.
    Brill TH; Kübler HR; Pohla H; Buchner A; Fend F; Schuster T; van Randenborgh H; Paul R; Kummer T; Plank C; Eisele B; Breul J; Hartung R; Schendel DJ; Gansbacher B
    Hum Gene Ther; 2009 Dec; 20(12):1641-51. PubMed ID: 19671000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigating Ras homolog gene family member C (RhoC) and Ki67 expression following external beam radiation therapy show increased RhoC expression in relapsing prostate cancer xenografts.
    Kristiansson A; Ceberg C; Bjartell A; Ceder J; Timmermand OV
    Biochem Biophys Res Commun; 2024 Oct; 728():150324. PubMed ID: 38968772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
    Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.